To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines

Inclusion criteria

• Men and women aged between 18 and 65
• Patients attaining grade 2 or 3 in the investigator's rating of glabellar lines severity at maximum frown
• Patients who voluntarily sign the informed consent
• Patients who can comply with the study procedures and visit schedule

Exclusion criteria

• Subjects who had facial plastic surgery (tissue augmentation, brow lift, and dermal resurfacing)treatment within 6 months. Those who had peeling or laser therapy
• Subjects with skin disorders, scar or infection around glabellar region
• Subjects who are taking Aspirin, NSAIDS or anti-coagulant
• Subjects with facial palsy or eyelid ptosis
• Subjects who diagnosed as neuromuscular junction disorder (e.g., myasthenia gravis, Lambert-Eaton Syndrome)
• Subjects with history of drug intoxication, alcohol abuse and/or depressive disorder
• Subjects with severe internal diseases (cardiovascular, respiratory, renal disease, liver disorder)
• Subjects who have previously been treated with botulinum toxin within 3 months (Botulinum toxin type A: 3months, type B: 4 months)
• Subject who have administered following drugs within the previous 4 months: Spectinomycin Hydrochloride, Aminoglycoside antibiotics, polypeptide antibiotics, tetracycline antibiotics, lincomycin antibiotics, muscle relaxants, anti-cholinergic agents, benzodiazepine and similar drugs, benzamide drugs, Tubocurarine-type muscle relaxants
• Subjects who have possibility to take the drugs listed above
• Subjects who have a plan to receive facial cosmetic procedures including dermal filler, chemical peeling and dermabrasion during study period
• Subjects who have glabellar lines that are unable to be improved with any physical method
• Subjects who have history of hypersensitivity to Botulinum toxin and other agents
• Subjects who are pregnant or breast-feeding
• Subjects who have a plan to be pregnant in 3months, or who are not doing contraceptive
• Subjects who participated in other studies within 30 days or were not passed over 5 times of half life for investigational product
• Subjects who are having trouble with acute disease
• Subjects who have taken any treatment that can affect to glabellar lines and/or any lines around forehead within the previous 6 months
• Subjects who are unable to communicate or follow the instructions
• Subjects who are not eligible for this study based on investigator's judgement